1.
Emerg Infect Dis
; 27(1)2021 01.
Article
in English
| MEDLINE
| ID: mdl-33227229
ABSTRACT
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
